United Kingdom

Vermillion Inc (VRML.OQ)

VRML.OQ on NASDAQ Stock Exchange Capital Market

15 Dec 2017
Change (% chg)

$0.03 (+1.49%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Vermillion reports third quarter loss of $0.06 per share
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Vermillion Inc :Vermillion reports third quarter 2017 results.Q3 revenue rose 12 percent to $699,000.Qtrly net loss per share attributable to common stockholders basic and diluted $0.06‍​.  Full Article

‍Aspira Labs says has entered into agreements to provide coverage for OVA1​
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Vermillion Inc :‍Aspira Labs says has entered into agreements to provide coverage for its in vitro diagnostic test, OVA1​.‍Aspira Labs- agreements with JVHL , QCA Health Plan of Arkansas, Louisiana State Medicaid Program, and Arizona State Medicaid Program​.  Full Article

Vermillion files for mixed shelf of up to $50 mln - SEC filing
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Vermillion Inc :Vermillion files for mixed shelf of up to $50 million - SEC filing.  Full Article

Vermillion reports Q2 loss per share $0.07
Wednesday, 10 Aug 2016 

Vermillion Inc : Vermillion reports second quarter 2016 results . Q2 loss per share $0.07 .Q2 revenue $709,000 versus $535,000.  Full Article

Vermillion Inc Q1 loss per share $0.09
Monday, 16 May 2016 

Vermillion Inc : Expect net cash utilization of $2.0 million - $3.0 million in q2 of 2016 . Vermillion reports first quarter 2016 results .Q1 loss per share $0.09.  Full Article

Vermillion, Inc announces FDA Clearance of Overa®
Monday, 21 Mar 2016 

Vermillion, Inc:Says Receipt of 510(k) marketing clearance from the FDA for successor to Vermillion's OVA1® test for determining ovarian cancer risk in conjunction with independent clinical and imaging assessment prior to planned surgery for a women with a pelvic mass.Says Second Generation OVA1 test, previously referred to as "OVA2", has been trademarked "Overa®.Overa replaces two of the five OVA1 biomarkers with HE4 and FSH in order to improve specificity and reduce the need for physicians to determine menopausal status when interpreting the test.  Full Article

Vermillion Inc adopts restructuring plan - Reuters
Friday, 12 Feb 2016 

Vermillion Inc:Restructuring headcount,other expenses targeting about 20% reduction in operating expenses in 2016 versus operating expenses in 2015 - RTRS.Says adopted a restructuring plan to streamline its organization - SEC filing.  Full Article

Reimbursement cuts on lab tests pressure US lab firm shares

Nov 20 A federal agency on Friday rolled out deep cuts to reimbursement rates for some lab tests under Medicare, a move that could save the government as much as $3 billion over five years, but hurt margins of U.S. laboratory companies.